The introduction of an authorised, more affordable semaglutide copy in South Africa marks a significant step in expanding access to diabetes treatment.Developed by Novo Nordisk and Acino, this medication targets type 2 diabetes management, not weight loss.The article highlights the importance of SAHPRA-approved products, warning against unregulated alternatives that pose health risks.While semaglutide has weight management benefits, its primary use is for diabetes and heart health.The collaboration aims to improve patient access to essential treatments, addressing affordability and supply challenges.Healthcare professionals stress the need for licensed procurement and caution against unverified sources.This development underscores the balance between public health needs and regulatory oversight in pharmaceutical access.